The Food and Drug Administration (FDA) recently announced measures it plans to take in order to process and approve progressively more complex novel and generic therapies. There are some key areas expected to boom over the next few years, including two particular ones. In this article Andrew S. Verderame at PharmaLex US discusses these two areas in details.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2019/07/The-FDA-is-shifting-focus-to-both-ends.pdf” width=”100%” height=”900px” style=”border:0;”]